Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Exclusion Criteria15

• Lymphoma involving the central nervous system or transformation to high-grade;
• Uncontrolled or significant cardiovascular diseases, including:
• New York Heart Association (NYHA) Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months prior to the first dose of the study drug, or arrhythmia requiring treatment at screening, with left ventricular ejection fraction (LVEF) \<50%;
• Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, or unclassified cardiomyopathy);
• History of clinically significant QTc interval prolongation, or QTc interval \>470 ms for females or \>450 ms for males at screening;
• Subjects with symptomatic coronary artery disease requiring medication;
• Poorly controlled hypertension (failure to achieve target blood pressure after at least one month of lifestyle modification and treatment with three or more antihypertensive drugs, including diuretics, at maximally tolerated doses, or requiring four or more antihypertensive drugs for effective control).
• Active bleeding within 2 months prior to screening, or current use of anticoagulants, or investigator-determined clear bleeding tendency;
• History of deep vein thrombosis or pulmonary embolism within the past six months;
• Urine protein ≥2+ and 24-hour urine protein quantification ≥2 g/24 hours;
• Clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction), or subjects with total gastrectomy;
• Current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, or other conditions affecting lung function;
• Pregnant or breastfeeding women, or subjects of childbearing potential unwilling to use contraception;
• Continuous use of drugs with moderate to strong cytochrome P450 CYP3A inhibition or strong induction effects;
• Other conditions deemed by the investigator as unsuitable for participation in this trial.